AR050341A1 - Compuestos derivados de piperidina, composicion farmaceutica en base al compuesto y su uso para preparar medicamentos - Google Patents

Compuestos derivados de piperidina, composicion farmaceutica en base al compuesto y su uso para preparar medicamentos

Info

Publication number
AR050341A1
AR050341A1 ARP050102507A ARP050102507A AR050341A1 AR 050341 A1 AR050341 A1 AR 050341A1 AR P050102507 A ARP050102507 A AR P050102507A AR P050102507 A ARP050102507 A AR P050102507A AR 050341 A1 AR050341 A1 AR 050341A1
Authority
AR
Argentina
Prior art keywords
alkyl
represents hydrogen
hydroxy
piperidine
compound
Prior art date
Application number
ARP050102507A
Other languages
English (en)
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of AR050341A1 publication Critical patent/AR050341A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Abstract

La presente se refiere a derivados de piperidina sustituidos por alquilo utiles como inhibidores de la recaptacion del neurotransmisor monoamina. En otros aspectos, la presente se refiere al uso de estos compuestos para preparar medicamentos y a composiciones farmacéuticas que incluyen los compuestos de la presente. Reivindicacion 1: Un derivado de piperidina de formula (1), cualquiera de sus isomeros o cualquier mezcla de sus isomeros, o una sal farmacéuticamente aceptable de los mismos, en la que: Ra representa hidrogeno o alquilo; en donde el alquilo se sustituye opcionalmente con uno o más sustituyentes seleccionados independientemente del grupo que incluye: halo, trifluorometilo, trifluorometoxi, ciano, hidroxi, amino, nitro, alcoxi, cicloalcoxi, alquilo, cicloalquilo, cicloalquilalquilo, alquenilo y alquinilo; X representa -O-, -S- o -NRc-; en donde Rc representa hidrogeno, alquilo, -C(=O)Rd o -SO2Rd; en donde Rd representa hidrogeno o alquilo; Rb representa un grupo arilo, en donde el grupo arilo se sustituye opcionalmente con uno o más sustituyentes seleccionados independientemente del grupo que incluye: halo, trifluorometilo, trifluorometoxi, ciano, hidroxi, amino, nitro, alcoxi, cicloalcoxi, alquilo, cicloalquilo, cicloalquilalquilo, alquenilo y alquinilo; cada uno de R2, R2', R3, R3', R5, R5', R6 y R6' independientemente uno del otro representa hidrogeno o alquilo; con la condicion que al menos uno de R2, R2', R3, R3', R5, R5', R6 y R6' represente alquilo; y con la condicion que el compuesto no sea 4-(4-hidroxi-fenoxi)-2,2,6,6-tetrametilpiperidina o 4-(4-metoxi-fenoxi)-2,2,6,6-tetrametilpiperidina.
ARP050102507A 2004-06-18 2005-06-17 Compuestos derivados de piperidina, composicion farmaceutica en base al compuesto y su uso para preparar medicamentos AR050341A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200400961 2004-06-18

Publications (1)

Publication Number Publication Date
AR050341A1 true AR050341A1 (es) 2006-10-18

Family

ID=37311739

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102507A AR050341A1 (es) 2004-06-18 2005-06-17 Compuestos derivados de piperidina, composicion farmaceutica en base al compuesto y su uso para preparar medicamentos

Country Status (9)

Country Link
US (3) US7547788B2 (es)
EP (1) EP1761493A2 (es)
JP (1) JP2008502651A (es)
CN (1) CN1960974A (es)
AR (1) AR050341A1 (es)
CA (1) CA2570075A1 (es)
MX (1) MXPA06013917A (es)
TW (1) TW200604173A (es)
WO (1) WO2005123679A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570075A1 (en) * 2004-06-18 2005-12-29 Neurosearch A/S Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20090124663A1 (en) * 2005-06-08 2009-05-14 Neurosearch A/S Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP2059506A1 (en) * 2006-08-30 2009-05-20 Neurosearch A/S Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
JP2011513355A (ja) * 2008-03-05 2011-04-28 ノイロサーチ アクティーゼルスカブ 新規な４−ベンズヒドロキシ−テトラアルキル−ピペリジン誘導体及びモノアミン神経伝達物質再取り込み阻害薬としてのその使用
US8546576B2 (en) * 2008-06-06 2013-10-01 Sk Biopharmaceuticals Co., Ltd. 3 or 4-substituted piperidine compounds
EP3145910B1 (en) * 2014-05-21 2018-07-11 Solvay Specialty Polymers USA, LLC. Piperidine-based stabilizers and polymers end-capped with the same
WO2015177193A1 (en) * 2014-05-21 2015-11-26 Solvay Specialty Polymers Usa, Llc Stabilizer compounds
MX2016000700A (es) 2015-01-22 2017-04-06 Evonik Degussa Gmbh Sintesis de compuestos de triacetonadiamina mediante procedimiento de aminacion reductora de triacetonadiamina y derivados de los mismos.
MX2016000701A (es) 2015-01-22 2016-11-24 Evonik Degussa Gmbh Proceso para preparar un compuesto de triacetonamina n-metil sustituida.
DE102016212379A1 (de) 2016-07-07 2018-01-11 Evonik Degussa Gmbh Verfahren zur Herstellung einer N-methylsubstituierten Triacetonaminverbindung
DE102016212378A1 (de) 2016-07-07 2018-01-11 Evonik Degussa Gmbh Synthese von Triacetondiaminverbindungen durch reduktive Aminierung ausgehend von Triacetondiamin und dessen Derivaten

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3684765A (en) 1970-01-08 1972-08-15 Sankyo Co Stabilization of synthetic polymers
GB1411782A (en) 1972-02-24 1975-10-29 Wyeth John & Brother Ltd Piperidine derivatives
US3907813A (en) 1973-09-11 1975-09-23 Janssen Pharmaceutica Nv Stereoisomeric forms of 4-anilino-3-methyl piperidines
US3923992A (en) * 1974-05-23 1975-12-02 Univ Mississippi Analgetic composition and method of use
FR2361880A1 (fr) 1976-04-29 1978-03-17 Science Union & Cie Nouvelles 4-amino piperidines, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
DE3218645A1 (de) * 1982-05-18 1983-11-24 Hoechst Ag, 6230 Frankfurt Fluoranverbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbbilder in kopiersystemen
JPS63206757A (ja) 1987-02-23 1988-08-26 Mitsubishi Paper Mills Ltd 電子写真感光体
US5019583A (en) * 1989-02-15 1991-05-28 Glaxo Inc. N-phenyl-N-(4-piperidinyl)amides useful as analgesics
US4939161A (en) 1989-05-12 1990-07-03 Boc, Inc. Analgesic N-aryl-N-[1-substituted-3,5-dimethyl-4-piperidinyl]amides
EP0461206B1 (en) 1989-09-09 1994-03-02 Sandoz-Patent-Gmbh Synthetic polyamides and their salts
PL185132B1 (pl) 1996-02-22 2003-02-28 Neurosearch As Pochodne tropanowe, ich wytwarzanie i zastosowanie, oraz zawierająca je kompozycja farmaceutyczna
JPH11348418A (ja) 1998-04-08 1999-12-21 Seiko Epson Corp 記録媒体および記録液
US6303627B1 (en) * 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake
WO2002089803A1 (en) * 2001-05-07 2002-11-14 Sankyo Company, Limited Composition for iontophoresis
ATE461174T1 (de) 2002-11-01 2010-04-15 Neurosearch As Neue piperidinderivate und deren verwendung als monoaminneurotransmitter-wiederaufnahmehemmer
CA2570075A1 (en) * 2004-06-18 2005-12-29 Neurosearch A/S Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Also Published As

Publication number Publication date
EP1761493A2 (en) 2007-03-14
JP2008502651A (ja) 2008-01-31
US20110086880A1 (en) 2011-04-14
US20090215820A1 (en) 2009-08-27
TW200604173A (en) 2006-02-01
US20070167487A1 (en) 2007-07-19
CA2570075A1 (en) 2005-12-29
CN1960974A (zh) 2007-05-09
MXPA06013917A (es) 2007-03-07
US7915419B2 (en) 2011-03-29
US7547788B2 (en) 2009-06-16
WO2005123679A3 (en) 2006-03-02
WO2005123679A2 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
AR050341A1 (es) Compuestos derivados de piperidina, composicion farmaceutica en base al compuesto y su uso para preparar medicamentos
CO6260076A2 (es) Derivados de uracilo o timina para el tratamiento de la hepatitis c
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR066881A1 (es) Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato.
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
CO5630004A2 (es) Derivados novedosos del 8-aza-biciclo [3,2,1] octano y su uso como inhibidores de la re-captacion de neurotransmisores monoaminicos
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
AR066095A1 (es) Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla
AR066882A1 (es) Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato.
AR043111A1 (es) Derivados monoacilados de o-fenilendiaminas
AR055060A1 (es) Derivados de n-(piridin-2-il)-sulfonamida
AR066583A1 (es) Derivados de 3,3-espiroindolinona
AR066460A2 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
AR058073A1 (es) Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
UY26048A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica
AR046308A1 (es) Derivados amida
AR039399A1 (es) Compuestos quimicos con actividad doble, procedimientos para su preparacion y composiciones farmaceuticas
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen
PE20091425A1 (es) Derivados de aminotiazol
CU20110169A7 (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
AR054102A1 (es) Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas
ECSP088257A (es) Derivados de amida
AR059546A1 (es) Derivados de cromen -2-ona utiles como inhibidores de recaptacion del neurotransmisor de monoamina

Legal Events

Date Code Title Description
FB Suspension of granting procedure